Erbitux and Cisplatin drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Erbitux (cetuximab) and Cisplatin (cisplatin). Common drug interactions include fatigue among females and dehydration among males.
The phase IV clinical study analyzes what interactions people have when they take Erbitux and Cisplatin. It is created by eHealthMe based on reports of 1,754 people who take the same drugs from the FDA, and is updated regularly.
What is Erbitux?
Erbitux has active ingredients of cetuximab. It is often used in cancer. eHealthMe is studying from 19,276 Erbitux users. Check the latest studies of Erbitux.
What is Cisplatin?
Cisplatin has active ingredients of cisplatin. It is often used in chemotherapy. eHealthMe is studying from 92,837 Cisplatin users. Check the latest studies of Cisplatin.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
1,754 people who take Erbitux and Cisplatin together, and have interactions are studied.
What are the common drug interactions of Erbitux and Cisplatin, by gender? *
What are the common drug interactions of Erbitux and Cisplatin, by age (0-1 to 60+)? *
What are the existing conditions these people have? *
* Approximation only. Some reports may have incomplete information.
Do you take Erbitux and Cisplatin?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Erbitux and Cisplatin:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Erbitux:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Cisplatin:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Erbitux and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Cisplatin and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Schlumbrecht MP, Hehr K, "Cisplatin-induced bradycardia and the importance of the QT interval", Journal of Oncology Pharmacy Practice, 2015 Jan .
- Gupta D, Shukla P, Bisht SS, Bhatt ML, Pant MC, Srivastava K, "Deep vein and artery thrombosis associated with cetuximab-based chemoradiotherapy", Indian journal of pharmacology, 2011 Jan .
- Schlumbrecht MP, Hehr K, "Cisplatin-induced bradycardia and the importance of the QT interval", Journal of Oncology Pharmacy Practice, 2015 Jan .
- Gupta D, Shukla P, Bisht SS, Bhatt ML, Pant MC, Srivastava K, "Deep vein and artery thrombosis associated with cetuximab-based chemoradiotherapy", Indian journal of pharmacology, 2011 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on cetuximab and cisplatin (the active ingredients of Erbitux and Cisplatin, respectively), and Erbitux and Cisplatin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Multivitamin cause Eye Movements - Uncontrollable? - 2 seconds ago
- Drug interactions of Gabapentin and Glumetza - 4 seconds ago
- Adcirca and Calcitriol drug interactions for men aged 60+ - 7 seconds ago
- Vitamin D and Lorazepam drug interactions for boys aged 0-1 - 10 seconds ago
- Could Loratadine cause Muscle Atrophy? - 13 seconds ago
- Ultracet vs. Sulindac, side effect and effectiveness comparison - 16 seconds ago
- Drug interactions of Miralax and Imiquimod - 16 seconds ago
- Could Prednisone cause Optic Neuritis? - 17 seconds ago
- Septra Ds and Albuterol drug interactions for men aged 60+ - 23 seconds ago
- Promethazine and Etoposide drug interactions for boys aged 2-9 - 23 seconds ago